GEN Exclusives

More »

GEN News Highlights

Back to Item »

FDA Okays Dyax’ Subcutaneous Kallikrein Inhibitor for Acute HAE

Cubist is separately developing the compound to reduce blood loss during on-pump cardiothoracic surgery.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?